A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE)
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Olodanrigan (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms EMPADINE
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 Apr 2019 This trial is discontinued in Finland (end date:22 Mar 2019), according to European Clinical Trials Database.
- 08 Apr 2019 Status changed from recruiting to discontinued.
- 05 Apr 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.